The updated guidelines include 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments.
The American Academy of Dermatology issued updates to the 2014 Guidelines for the Management of Atopic Dermatitis. The new guidelines were published in the Journal of the American Academy of Dermatology earlier this month.
A multidisciplinary work group developed 11 evidence-based recommendations for the management of atopic dermatitis in adults using phototherapy and systemic treatments. These include injectable biologics, oral Janus kinase (JAK) inhibitors, and older immunosuppressants, antimetabolites, and corticosteroids.
For adults with more severe atopic dermatitis or dermatitis resistant to topical treatments, the work group made strong recommendations for the use of the monoclonal antibodies Dupixent (dupilumab) and Adbry (tralokinumab). Strong recommendations were also made for the JAK inhibitors Rinvoq (upadacitinib), Cibinqo (abrocitinib), and (Olumiant) baricitinib.
All but Olumiant are FDA-approved to treat moderate to severe atopic dermatitis. Olumiant is approved for this use in Europe and is approved for rheumatoid arthritis in the United States. The drug is currently under FDA regulatory review for the potential treatment of atopic dermatitis.
Phototherapy and the antimetabolite methotrexate were conditionally recommended with proper monitoring. The immunosuppressants mycophenolate, azathioprine, and cyclosporine were also conditionally recommended with appropriate monitoring.
Lastly, the work group conditionally recommended against the use of systemic corticosteroids, adding that their use should be limited to acute, severe exacerbations. These drugs should only be used as a short-term bridge therapy to other corticosteroid-sparing treatments.
A future publication will cover guidelines for the management of pediatric atopic dermatitis the authors wrote.
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More